dc.creator | Anaya, Juan-Manuel | |
dc.creator | Sany, J. | |
dc.creator | Combe, B | |
dc.creator | Didry, C | |
dc.creator | Gutiérrez-Peláez, Miguel | |
dc.date.accessioned | 2020-08-19T14:44:38Z | |
dc.date.accessioned | 2022-09-22T14:45:59Z | |
dc.date.available | 2020-08-19T14:44:38Z | |
dc.date.available | 2022-09-22T14:45:59Z | |
dc.date.created | 2020-08-19T14:44:38Z | |
dc.identifier | ISSN: 1165-0478 | |
dc.identifier | https://repository.urosario.edu.co/handle/10336/27919 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/3441904 | |
dc.description.abstract | Objectives: Methotrexate is successfully used in the treatment of arthritis but little is known about its effects on extra-articular manifestations of rheumatoid arthritis. We focused this work on the incidence and clinical course of extra-articular manifestations during long-term treatment with methotrexate.Methods: The effect of methotrexate on extra-articular manifestations was investigated in 176 patients with rheumatoid arthritis who had obtained, in a prospective study, a good clinical response to methotrexate (10 mg/week) taken for 33 months (range 4-68).Results: Before taking methotrexate, 44 patients (25.1%) had extra-articular manifestations: nodules (n = 40) and vasculitis (n = 9). With methotrexate, nodulosis and vasculitis were stable in 31 cases, improved in 3 and worsened in 10 (23%). Among the 132 patients without extra-articular manifestations before methotrexate therapy, 15 (11%) developed accelerated nodulosis preferentially located on the fingers, 7 had a vasculitis and 3 a pericarditis during methotrexate therapy. Extra-articular manifestations occurred between 1 and 24 months of initiating methotrexate therapy. Rheumatoid factor was positive in 88% of the patients with extra-articular manifestations. No relationship was noted between extra-articular manifestations and HLA type or antinuclear antibodies. In 3 out of 4 patients who developed accelerated nodulosis while taking methotrexate, the addition of hydroxychloroquine (400 mg/day) resulted in a significant reduction in the number and size of the nodules within 3 to 10 months after starting combined therapy.Conclusion: These data suggest that methotrexate is not effective in the treatment of extra-articular manifestations in rheumatoid arthritis and that nodulosis may occur in about 11% of patients taking methotrexate therapy for rheumatoid arthritis. The combination of hydroxychloroquine and methotrexate may have a beneficial effect on nodulosis that needs to be evaluated. | |
dc.language | eng | |
dc.publisher | National Center for Biotechnology Information | |
dc.relation | The European journal of medicine, ISSN: 1165-0478, Vol.2, No.3 (1993); pp. 153-160 | |
dc.relation | https://pubmed.ncbi.nlm.nih.gov/8261056/ | |
dc.relation | 160 | |
dc.relation | No. 3 | |
dc.relation | 153 | |
dc.relation | The European journal of medicine | |
dc.relation | Vol. 2 | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.rights | Bloqueado (Texto referencial) | |
dc.source | The European journal of medicine | |
dc.source | instname:Universidad del Rosario | |
dc.source | reponame:Repositorio Institucional EdocUR | |
dc.title | Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis | |
dc.type | article | |